Twenty-four-month real-life treatment outcomes of polypoidal choroidal vasculopathy versus type 1 macular neovascularization in Caucasians.
Matteo AiraldiAlessandro InvernizziVuong NguyenStela VujosevicFederico RicciPietro MonacoMarco NassisiBarthelmes DanielMark C GilliesFrancesco ViolaPublished in: Clinical & experimental ophthalmology (2023)
PCV had slightly better VA outcomes over 24 months of treatment than type 1 MNV after receiving less anti-VEGF injections. These results suggest a possible overlap of the two clinical entities with similar visual prognosis in Caucasians.